International Study for Treatment of High Risk Childhood Relapsed ALL 2010

Status Recruiting

Clinical Trial Summary

The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the integration of new agents.

Clinical Trial Description

Though survival of children with acute lymphoblastic leukemia (ALL) has considerably improved over the past few decades, relapsed ALL remains a leading cause of mortality in children with cancer. Risk has been defined by the International (I) Berlin, Frankfurt, Münster (BFM) Study Group (SG) based on duration of first remission, immunophenotype of malignant clone, and site of relapse. Patients classified as high risk (HR) by these criteria have poor response rates to standard induction therapy, high rates of subsequent relapse and require an allogeneic hematopoetic stem cell transplantation (allo-HSCT) for consolidation of 2nd remission. Over the last decade members of the I-BFM-SG have investigated the use of different combinations of conventional cytotoxic agents. Even with allo-HSCT, none of these approaches have improved outcome above 40%. Therefore, for HR patients there is a need to investigate the curative potential of new agents combined with systemic therapy. The proteasome inhibitor bortezomib has shown synergistic activity with acceptable toxicity when combined with corticosteroids, anthracyclines and alkylating agents in adult patients with cancer as well as with dexamethasone, doxorubicin, vincristine and polyethylene glycol (PEG) asparaginase in children with refractory or relapsed ALL. In the I-BFM-SG International Study for Treatment of High Risk Childhood Relapsed ALL (IntReALL) HR 2010 study, the potential of Bortezomib combined with a modified ALL relapse protocol 3 (R3) backbone as induction regimen for HR patients to improve complete 2nd remission (CR2) rates will be investigated in a randomized phase II design. Induction is followed by conventional intensive consolidation. After termination of the trial patients may be subjected to an investigational window, before all of them receive allo-HSCT. ;

Study Design

Related Conditions & MeSH terms

Acute Lymphoblastic Leukemia (ALL)
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trial Details

NCT number	NCT03590171
Study type	Interventional
Source	Charite University, Berlin, Germany
Contact	Arend von Stackelberg, MD
Phone	+49(0)30-450666
Email	arend.stackelberg@charite.de
Status	Recruiting
Phase	Phase 2
Start date	September 1, 2017
Completion date	December 31, 2027

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02259348` - Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation	Phase 2
Recruiting	`NCT01351545` - A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting	`NCT02894645` - Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study	Phase 4
Completed	`NCT03236857` - A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies	Phase 1
Completed	`NCT03181126` - A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma	Phase 1
Recruiting	`NCT05291390` - Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)	Phase 2
Recruiting	`NCT01758042` - Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders	N/A
Completed	`NCT01221857` - Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies	Phase 1/Phase 2
Completed	`NCT01282593` - Potential Role of CD9 and Implication of Motility Process in Pathogenesis of TEL/ALM1-positive ALL Relapses (LAL TEL/ALM1 and CD9).	N/A
Completed	`NCT01885897` - IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT	Phase 1/Phase 2
Completed	`NCT03067584` - Genetic Study of Familial Acute Lymphoblastic Leukemia
Recruiting	`NCT05884333` - Cord Blood Transplant in Adults With Blood Cancers	Phase 2
Terminated	`NCT02338050` - Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2
Completed	`NCT01802814` - International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010	Phase 3
Completed	`NCT00495079` - Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia	Phase 2
Completed	`NCT01735955` - Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study	Phase 4
Terminated	`NCT01439347` - A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL	Phase 3
Recruiting	`NCT04929899` - Bright Ideas - CIN Feasibility Study	N/A
Recruiting	`NCT02061800` - CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant	Phase 1/Phase 2
Terminated	`NCT01050764` - Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells	Phase 1/Phase 2